Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: progenity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2021 | $59.00 → $57.00 | Overweight → Equal-Weight | Stephens |
| 10/14/2021 | $4.00 | Buy | HC Wainwright & Co. |
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy. Under the terms of the agreement, Progenity is contributing all assets related to the technologies to newly formed Enumera Molecular, Inc., which intends to develop and commercialize them. Progenity will receive an ownership stake in the company. "Enumera Molecular was founded as a life science tools company focused on developing a scalab
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company's focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics. "As we complete our strategic transformation, we are launching Biora Therapeutics to reflect our mission going forward, which is to reimagine therapeutics and their delivery," said Adi Mohanty, Chief Executive Officer. "By creating innovative smart pills designed for tar
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year's meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022. Details of the presentations are as follows: Abstract Titl
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company's Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2021. In the fourth quarter Progenity made important progress in transforming into an innovation-led bi
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code:
Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery A Clinical Device Performance Study in Patients with Ulcerative Colitis is Now Recruiting SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced progress with its clinical device performance study plan, evaluating the device function and safety of its Drug Delivery System (DDS) capsule. Progenity's first clinical device performance study evaluated the safety and tolerability of its DDS capsule and validation of the device's localization and delivery function in healthy volunteers. The DDS capsule was ingested o
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, and will take place in person and virtually May 21-24, 2022. Details of the presentations are as follows: Abstract Title: Tofacitinib Tissue Exposure Correlates with Endoscopic Outco
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 18, 2022. Dr. Geert D'Haens and Mr. Joep van Oostrom shared a poster titled "Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe UC," which explores potential causes for the 30% of patients who are primary non-responders to anti-TNF therapies. The pro-inflammatory cytokine interleukin 6 (IL6) was ob
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code:
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 9763335. A live webcast and archive of the call will be available online from the investor relations section of the compa
Announced successful completion of the validation study PRO-104 for the Preecludia™ rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved promising results with the prototype autonomous Oral Biotherapeutics Delivery System in a single oral dose study in a porcine model for lead candidate PGN-OB1 Implemented cost-cutting measures expected to result in approximately $97 million of cost savings on an annual run-rate basis Management will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the fields of g
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 8635609. A live webcast and archive of the call will be available online from the investor relations section of the company
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M in gross proceeds from a recent private placement with two leading healthcare-focused investment funds Maintains 2021 revenue guidance range Management will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided corporate updates and reported financial result
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has commenced an underwritten public offering of $25 million of shares of its common stock. In addition, Progenity is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $3.75 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether
Stephens downgraded Progenity from Overweight to Equal-Weight and set a new price target of $57.00 from $59.00 previously
HC Wainwright & Co. initiated coverage of Progenity with a rating of Buy and set a new price target of $4.00
Raymond James downgraded Progenity from Outperform to Market Perform
Robert W. Baird downgraded Progenity from Outperform to Neutral and set a new price target of $2.00 from $4.00 previously
Baird downgraded Progenity from Outperform to Neutral and set a new price target of $2.00 from $4.00 previously
Wells Fargo reiterated coverage of Progenity with a rating of Underweight and set a new price target of $2.00 from $4.00 previously
Raymond James reiterated coverage of Progenity with a rating of Outperform and set a new price target of $7.00 from $10.00 previously
Wells Fargo & Company downgraded Progenity from Overweight to Underweight
Wells Fargo downgraded Progenity from Overweight to Underweight and set a new price target of $5.00 from $11.00 previously
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G/A - PROGENITY, INC. (0001580063) (Subject)
SC 13D/A - PROGENITY, INC. (0001580063) (Subject)
SC 13G - PROGENITY, INC. (0001580063) (Subject)
SC 13D/A - PROGENITY, INC. (0001580063) (Subject)
SC 13D/A - PROGENITY, INC. (0001580063) (Subject)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
DEFA14A - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
DEF 14A - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors. "As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success," said Eric d'Esparbes, Chief Financial Officer and interim CEO. "To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase o
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi's medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. "As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems of the future. We are delighted that Surbhi Sarna has agreed to join the Progenity Board of Directors to support these efforts," said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations. In this advisory role, Dr. Lavin will work with Progenity's senior management in the areas of strategy, business development, investor outreach, and shareholder value creation as the company transitions its focus towards biotechnology innovation. Dr. Lavin previously served as a Managing Director in equity research at BTIG and Lazard Capital Markets where he covered medical devices and diagnostics, and he currently runs his own firm, Alpha Lavin Advisors,